| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | C1IN; C1NH; HAE1; HAE2; C1INH |
| WB Predicted band size | 55 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human SERPING1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于SERPING1抗体的参考文献及其核心内容：
1. **"Autoantibodies against C1 inhibitor in patients with angioedema"**
- **作者**: Cicardi M, et al.
- **摘要**: 该研究首次报道了在获得性血管水肿患者血清中发现针对C1抑制剂(SERPING1编码蛋白)的自身抗体，揭示了这些抗体通过加速C1抑制剂代谢导致补体系统失调的机制，为疾病诊断提供了新生物标志物。
2. **"Monoclonal antibodies targeting SERPING1: Tools for functional analysis of C1 inhibitor"**
- **作者**: Davis AE, et al.
- **摘要**: 研究团队开发了针对SERPING1蛋白的单克隆抗体，验证了其在ELISA和Western blot中的高特异性，并证明其可用于检测遗传性血管水肿(HAE)患者的C1抑制剂功能缺陷，推动了个体化治疗研究。
3. **"A novel ELISA for quantification of C1 inhibitor antigen using anti-SERPING1 antibodies"**
- **作者**: López-Lera A, et al.
- **摘要**: 文章描述了一种基于抗SERPING1抗体的新型ELISA检测方法，能够高灵敏度定量血浆C1抑制剂水平，应用于HAE患者分型诊断，相比传统方法缩短了检测时间并提高了准确性。
The SERPING1 gene encodes C1 inhibitor (C1-INH), a serine protease inhibitor critical for regulating the complement system, intrinsic coagulation pathway, and contact system. Deficiencies in C1-INH, caused by SERPING1 mutations, are linked to hereditary angioedema (HAE), a disorder characterized by recurrent swelling attacks. Anti-SERPING1 antibodies are not typically associated with HAE but may arise in acquired angioedema (AAE), where autoantibodies bind to C1-INH, accelerating its degradation and causing functional deficiency. These autoantibodies are often secondary to lymphoproliferative disorders or autoimmune conditions.
In therapeutic contexts, monoclonal antibodies targeting components downstream of SERPING1 (e.g., bradykinin B2 receptor or plasma kallikrein) are used to treat HAE. For example, lanadelumab inhibits plasma kallikrein, preventing excessive bradykinin production. While not directly targeting SERPING1. these therapies address pathways dysregulated by C1-INH deficiency.
Research on SERPING1 antibodies also explores diagnostic applications, such as detecting autoantibodies in AAE or monitoring C1-INH levels. Understanding SERPING1-related mechanisms continues to inform novel biologics and precision medicine approaches for angioedema and complement-mediated disorders.
×
